Mark Brönstrup’s research group aims to identify and optimise new antibacterial and antiviral agents. They therefore test collections of various compounds using newly developed assay systems and are expanding the DZIF infrastructure in collaboration with the European network EU OPENSCREEN. In addition, they use rational design approaches and explore natural substances to ascertain the starting points for drug development. In order to find lead compounds and candidates for clinical development, the researchers optimise active substances using medicinal chemistry and also profile them biologically, both in vitro and in vivo. Currently, they are supporting projects in the research fields “Novel Antibiotics” and “Tuberculosis” as well as in the DZIF infrastructure “Novel Antivirals”.